Crescendo Biologics and Takeda Enter Collaboration for Humabody®-based Therapeutics Worth up to $790m
Collaboration to generate tumor targeting drug conjugates and immuno-oncology therapeutics Crescendo Biologics Limited (Crescendo), the…
read more
Crescendo Biologics is developing two proprietary platforms for biological therapeutics from the Babraham Institute: ribosome display for the optimization of antibodies and a transgenic mouse which produces heavy chain only antibodies.
